An economic evaluation of the randomized controlled trial of topical corticosteroid and home‐based narrowband ultraviolet B for active and limited vitiligo (the HI‐Light Vitiligo Trial)*
British Journal of Dermatology2020Vol. 184(5), pp. 840–848
Citations Over Time
Tracey Sach, Kim S Thomas, Jonathan Batchelor, A. Perways, Joanne R Chalmers, Rachel Haines, Garry Meakin, Lelia Duley, Jane Ravenscroft, Andy Rogers, Miriam Santer, Wei Tan, Jennifer White, Maxine E Whitton, Hywel C Williams, Seau Tak Cheung, Hamdi Hamad, Andrew Wright, John R Ingram, N. J. Levell, J. M. R. Goulding, Areti Makrygeorgou, Anthony Bewley, Malobi Ogboli, J. Stainforth, Adam Ferguson, Bisola Laguda, Shyamal Wahie, Robert Ellis, J. Azad, Amirtha Rajasekaran, Viktoria Eleftheriadou, Alan Montgomery
Abstract
Combination treatment, compared with TCS alone, has a lower incremental cost per additional successful treatment than NB-UVB only. Combination treatment would be considered cost-effective if decision makers are willing to pay £1932 per additional treatment success.
Related Papers
- Observation of the Curative Effect of Calcipotriol Ointment Combine with Narrow-band Ultraviolet B on Psoriasis(2010)
- → Alteration of Cell Mediated Immunity in Vitiligo Patients Using Narrow Band UVB as a Treatment.(2019)
- → Tacrolimus versus narrowband ultraviolet b in the treatment of vitiligo: a clinical and laboratory evaluation(2017)
- → Narrow-band ultraviolet B in the treatment of vitiligo(2010)
- → Faculty Opinions recommendation of The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo.(2018)